Huntington Disease
Conditions
Brief summary
The goal of this observational study is to learn about the first signs of disease in young adult carriers of the gene for Huntington's disease. The main questions to answer are: * what are the earliest signs of the disease? * can we identify the best time to intervene with treatment to prevent or delay onset of symptoms? * can we identify the most reliable markers of disease for use in prevention trials? Participants will undergo the following assessments: * clinical examination * cognitive and neuropsychiatric testing * brain imaging * biofluid sampling Researchers will compare gene carriers with matched controls to see if any of these measures show evidence of early disease effects.
Detailed description
We will undertake follow up assessments of the HD-YAS cohort comprising far-from-onset premanifest mutation carriers (preHD) (n=64) and controls, matched for age, sex and education (n=67). These assessments will occur approximately 4.5 and 6 years after their baseline assessment. They will include * detailed clinical assessment * cognitive testing using CANTAB and the EMOTICOM * neuropsychiatric assessment * neuroimaging including 3T volumetric MRI, NODDI, resting state fMRI and multiparametric mapping. A subset of 20 gene carriers and 20 controls will undergo 7T imaging * blood and CSF sampling We will compare change over time in preHD and control groups and model disease burden influence (an early natural history proxy) within the preHD group. These analyses will incorporate previous baseline measurements (providing three timepoints). We will create a data-driven natural history of pathological changes across the pre-clinical period in HD and estimate longitudinal models of age and CAG-dependence on the outcomes, providing a critical tool to increase power.
Interventions
OTHERNo intervention
Study is observational
Sponsors
University of Iowa
University of Cambridge
University of Glasgow
University College, London
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 47 Years
Inclusion criteria
For the Healthy Control group, participants eligible are persons who meet the following criteria: 1. Are capable of providing informed consent and 2. Are capable of complying with study procedures and 3. Are aged between 18-47 years old and 4. Have no known family history of HD (gene negative); or 5. Have known family history of HD but have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG \< 36\*) (family control or community control) For the Young Adult Premanifest HD group, participants eligible are persons who meet the following criteria: 1. Are capable of providing informed consent and 2. Are capable of complying with study procedures and 3. Are aged between 18-47 years old and 4. Have CAG expansion ≥ 40; 5. New participants must have a DBS \<240
Exclusion criteria
Current use of investigational drugs or participation in a clinical drug trial within 30 days prior to study visit; or b. Current intoxication, drug or alcohol abuse or dependence; or c. If using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to study visit; or d. Significant medical, neurological or psychiatric co-morbidity likely, in the judgment of the Principal Investigator, to impair participant's ability to complete essential study procedures; or e. Predictable non-compliance as assessed by the Principal Investigator; or f. Inability or unwillingness to undertake any of the essential study procedures; or g. Needle phobia: or h. Contraindication to MRI, including, but not limited to, MR-incompatible pacemakers, recent metallic implants, foreign body in the eye or other indications, as assessed by a standard pre-MRI questionnaire;or i. Pregnant (as confirmed by urine pregnancy test); or j. Claustrophobia, or any other condition that would make the subject incapable of undergoing an MRI. For CSF collection: 1. Needle phobia, frequent headache, significant lower spinal deformity or major surgery; or 2. Antiplatelet or anticoagulant therapy within the 14 days prior to sampling visit, including but not limited to: aspirin, clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban and apixaban; or 3. Clotting or bruising disorder; or 4. Screening blood test results outside the clinical laboratory's normal range for the following: white cell count, neutrophil count, lymphocyte count, haemoglobin (Hb), platelets, prothrombin time (PT) or activated partial thromboplastin time (APTT); or 5. Screening blood test results for C-reactive protein (CRP)\>2× upper limit of normal; or 6. Exclusion during history or physical examination, final decision to be made by the Principal Investigator; including but not limited to: i any reason to suspect abnormal bleeding tendency, e.g. easy bruising, petechial rash; or ii any reason to suspect new focal neurological lesion, e.g. new headache, optic disc swelling, asymmetric focal long tract signs; or iii any other reason that, in the clinical judgment of the operator or the Principal Investigator, it is felt that lumbar puncture is unsafe. For Optional 7T MRI and MEG 1. Contraindication to MRI, including, but not limited to, MR-incompatible pacemakers, recent metallic implants, foreign body in the eye or other indications, as assessed by a standard pre-MRI questionnaire; or 2. Pregnant (as confirmed by urine pregnancy test); or 3. Claustrophobia, or any other condition that would make the subject incapable of undergoing an MRI; or 4. Tattoos that fall above the line defined by the crease of the elbow or on the genitals.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brain volume in ml | Baseline, 4.5 years, 6 years | Global and regional measures of brain volume |
| Biofluids in grams per litre | Baseline, 4.5 years, 6 years | Blood and CSF measures |
| Cognition (raw scores) | Baseline, 4.5 years, 6 years | Cognitive tests including CANTAB and EMOTICOM |
Countries
United Kingdom
Outcome results
None listed